Adjunctive Subgingival Pomegranate Peel Extract Gel for Stage II-III Periodontitis
Adjunctive Subgingival Pomegranate Peel Extract Gel for Stage II-III Periodontitis: A Randomized Split-Mouth Trial
gehad samy
32 participants
Jul 1, 2026
INTERVENTIONAL
Conditions
Summary
This randomized, triple-blind, placebo-controlled split-mouth clinical trial aims to evaluate the clinical and biochemical efficacy of subgingival pomegranate peel extract gel as an adjunct to scaling and root planing (SRP) in the treatment of Stage II-III periodontitis. Thirty-two participants diagnosed with Stage II-III periodontitis will receive SRP in all selected periodontal sites. Test sites will receive locally delivered pomegranate peel extract gel, while contralateral control sites will receive a placebo gel. Clinical periodontal parameters, including probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), bleeding on probing (BOP), and gingival crevicular fluid levels of matrix metalloproteinase-8 (MMP-8), will be assessed at baseline, 1 month, 3 months, and 6 months to evaluate whether adjunctive pomegranate peel extract gel improves periodontal healing compared with SRP alone.
Eligibility
Inclusion Criteria8
- Adults aged 30 to 60 years.
- Systemically healthy individuals.
- Diagnosis of Stage II or Stage III periodontitis according to the 2018 Classification of Periodontal and Peri-Implant Diseases and Conditions.
- Presence of at least 20 natural teeth.
- Presence of at least two non-adjacent periodontal pockets (≥5 mm) located in different quadrants suitable for split-mouth allocation.
- Clinical attachment loss consistent with Stage II or Stage III periodontitis.
- Ability and willingness to comply with the study protocol and attend all follow-up visits.
- Provision of written informed consent.
Exclusion Criteria8
- Current smokers or users of any tobacco products.
- Pregnant or lactating women.
- Patients with systemic diseases known to affect periodontal status or wound healing (e.g., uncontrolled diabetes mellitus, immunodeficiency disorders, osteoporosis requiring antiresorptive therapy).
- Use of systemic antibiotics, corticosteroids, immunosuppressive agents, or non-steroidal anti-inflammatory drugs within the previous 3 months.
- Periodontal therapy received within the previous 6 months.
- History of allergy or hypersensitivity to pomegranate or any component of the study materials.
- Orthodontic treatment during the study period.
- Participation in another clinical trial within the previous 6 months.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Locally delivered subgingival gel containing pomegranate peel extract administered after scaling and root planing.
Placebo gel without active ingredient, identical in appearance and consistency to the experimental gel, administered after scaling and root planing.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07725393